You are here

ALLO-329

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Drugs.com

Wed, 04/16/25 - 10:55 pm

systemic lupus erythematosus

idiopathic inflammatory myopathy

diffuse systemic sclerosis